Pigment epithelial detachment response to aflibercept in neovascular age-related macular degeneration refractory to ranibizumab: time course and drug effects

De Massougnes, Sophie; Dirani, Ali; Ambresin, Aude; Decugis, Doris; Marchionno, Laetitia; Mantel, Irmela

doi:10.1097/IAE.0000000000000813

Scientific article

English

Pigment epithelial detachment response to aflibercept in neovascular age-related macular degeneration refractory to ranibizumab: time course and drug effects

ContributorsDe Massougnes, Sophie; Dirani, Ali; Ambresin, Aude; Decugis, Doris; Marchionno, Laetitia; Mantel, Irmela

Published inRetina, vol. 36, no. 5, p. 881-888

Publication date2016

Abstract

To investigate the time course of pigment epithelium detachment (PED) height and its change after anti-vascular endothelial growth factor switch from ranibizumab to aflibercept in neovascular age-related macular degeneration.

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département des neurosciences cliniques

Research groups

Ophtalmologie expérimentale (925)

Citation (ISO format)

DE MASSOUGNES, Sophie et al. Pigment epithelial detachment response to aflibercept in neovascular age-related macular degeneration refractory to ranibizumab: time course and drug effects. In: Retina, 2016, vol. 36, n° 5, p. 881–888. doi: 10.1097/IAE.0000000000000813

Article (Published version)

Identifiers

PID : unige:93154
DOI : 10.1097/IAE.0000000000000813
PMID : 27115852

ISSN of the journal1539-2864

365views

0downloads

Creation30/11/2016 09:32:00

First validation30/11/2016 09:32:00

Update time15/03/2023 01:32:11

Status update15/03/2023 01:32:10

Last indexation03/10/2024 08:59:10

Archive ouverte UNIGE

Pigment epithelial detachment response to aflibercept in neovascular age-related macular degeneration refractory to ranibizumab: time course and drug effects

To investigate the time course of pigment epithelium detachment (PED) height and its change after anti-vascular endothelial growth factor switch from ranibizumab to aflibercept in neovascular age-related macular degeneration.

Technical informations